Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy

Adoptive or active cancer immunotherapy can fail owing to the inefficient recruitment of effector leukocytes to malignant lesions. The intratumoral injection of recombinant proteins comprising a chemokine-derived domain linked to the mucin stalk of chemokine (C-X3-C motif) ligand 1 (CX3CL1) and a gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Peter J, Muenchmeier, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887060/
https://www.ncbi.nlm.nih.gov/pubmed/24427544
http://dx.doi.org/10.4161/onci.26619
_version_ 1782478965104967680
author Nelson, Peter J
Muenchmeier, Niklas
author_facet Nelson, Peter J
Muenchmeier, Niklas
author_sort Nelson, Peter J
collection PubMed
description Adoptive or active cancer immunotherapy can fail owing to the inefficient recruitment of effector leukocytes to malignant lesions. The intratumoral injection of recombinant proteins comprising a chemokine-derived domain linked to the mucin stalk of chemokine (C-X3-C motif) ligand 1 (CX3CL1) and a glycosylphosphatidylinositol anchor can specifically enhance the recruitment of effector cell subsets to solid tumors.
format Online
Article
Text
id pubmed-3887060
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38870602014-01-14 Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy Nelson, Peter J Muenchmeier, Niklas Oncoimmunology Author's View Adoptive or active cancer immunotherapy can fail owing to the inefficient recruitment of effector leukocytes to malignant lesions. The intratumoral injection of recombinant proteins comprising a chemokine-derived domain linked to the mucin stalk of chemokine (C-X3-C motif) ligand 1 (CX3CL1) and a glycosylphosphatidylinositol anchor can specifically enhance the recruitment of effector cell subsets to solid tumors. Landes Bioscience 2013-11-01 2013-10-10 /pmc/articles/PMC3887060/ /pubmed/24427544 http://dx.doi.org/10.4161/onci.26619 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Nelson, Peter J
Muenchmeier, Niklas
Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title_full Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title_fullStr Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title_full_unstemmed Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title_short Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
title_sort membrane-anchored chemokine fusion proteins: a novel class of adjuvants for immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887060/
https://www.ncbi.nlm.nih.gov/pubmed/24427544
http://dx.doi.org/10.4161/onci.26619
work_keys_str_mv AT nelsonpeterj membraneanchoredchemokinefusionproteinsanovelclassofadjuvantsforimmunotherapy
AT muenchmeierniklas membraneanchoredchemokinefusionproteinsanovelclassofadjuvantsforimmunotherapy

Ejemplares similares